Nevro Corp., a Menlo Park, California-based neuromodulation company focused on relief of chronic pain, has completed a $58m financing.
The round was led by new investor Johnson & Johnson Development Corporation (JJDC), with participation from existing backers Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Mayo Clinic, MPM Capital, and Three Arch Partners.
The company intends to use the funds to advance a pivotal clinical study in the U.S. and expand internationally.
Nevro Corp., which was founded in 2007 and is led by CEO Michael DeMane, has already received CE mark for its Nevro Spinal Cord Stimulation System, which is now commercially available at leading centers outside the United States.
FinSMEs
19/07/2011